Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693677 | 0.92 | USP2 (0.44) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL34473382 | 0.91 | PKM (0.45) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL2157135 | 0.91 | USP2 (0.51) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL21963889 | 0.88 | PKM (0.47) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL16986998 | 0.88 | PKM (0.49) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL4295685 | 0.88 | PKM (0.49) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL3160087 | 0.87 | USP2 (0.45) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL963907 | 0.87 | USP2 (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL1958618 | 0.87 | PKM (0.48) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL4129353 | 0.87 | PKM (0.48) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| CN-116034107-A | Quinuclidinone analogs as anticancer agents | 新波制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021078021-A1 | SMALL MOLECULAR COMPOUND | 嘉兴特科罗生物科技有限公司 | 2021-04-29 | — | — | WO | disclosed |
| US-9862720-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9771369-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771369-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150284397-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-10-08 | — | — | US | disclosed |
| WO-2015134536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
| EP-1989200-A2 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELI LILLY AND COMPANY (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007092095-A2 | [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | PKM 986/4885USP2 4272/4885SMN1; SMN2 411/4885 |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, CNKSR1, NQO1 | PKM 1595/4885USP2 3871/4885SMN1; SMN2 2023/4885 |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | PKM 891/4885USP2 1936/4885SMN1; SMN2 4233/4885 |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, PRMT1, PRMT7 | PKM 1083/4885USP2 3747/4885SMN1; SMN2 2345/4885 |
| US-20150284397-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | PKM 440/4885USP2 3192/4885SMN1; SMN2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.